Lonza Capabilities Update September 2026: Viral Vectors

In vivo CAR-T could change cell therapy by removing the complex logistics, long lead times, and high costs of ex vivo manufacturing. But when a lentiviral vector moves from being a starting material to being the drug product itself, the requirements change. Purity, potency, genome integrity, stability, and formulation all come under much closer scrutiny, while regulatory expectations are still evolving.

In this presentation, Bingnan Gu, Head of Viral Vector R&D at Lonza, explains what it takes to make LVV truly fit for in vivo use. Drawing on real client case studies, he shows how a feasibility-first development approach and an enhanced downstream process can help close the gap between a targeted vector concept and a clinical-ready product. He also introduces two new analytical tools that shed light on what’s actually inside an LVV sample, and why that matters for predicting performance.